 |
answer text |
<p>The Department has no plans to establish a new assessment process for the evaluation
of rare disease treatments that do not meet the criteria for the National Institute
for Health and Care Excellence (NICE) Highly Specialised Technology appraisal route.
NICE develops guidance on most new drugs through its technology appraisal programme,
and has been able to recommend a number of drugs for rare diseases for routine use
on the National Health Service.</p><p> </p><p>There is an established topic selection
process for the technology appraisal and highly specialised technology evaluation
programme that includes a public consultation and is designed to ensure that treatments
are only referred for assessment by NICE where its guidance will add value.</p>
|
 |
